Monday 16/11/2026
| Unit | 3Q26 | 3Q25 | YoY | 9M26 | 9M25 | YoY | |
| Total Revenues | $MM | 59 | 43 | +35% | 151 | 134 | +13% |
| Net Income Attributable to SBC Medical | $MM | 16 | 13 | +22% | 38 | 37 | +2% |
| Net Income Margin | % | 27 | 30 | (3)pt | 25 | 27 | (2)pt |
| Adjusted EBITDA 1 | $MM | 28 | 17 | +66% | 66 | 57 | +17% |
| Adjusted EBITDA Margin 1 | % | 47 | 38 | +9pt | 44 | 42 | +2pt |
| ROE (Annualized) 5 | % | 23 | 23 | (0)pt | 19 | 22 | (3)pt |
| Basic EPS 6 | $ | 0.15 | 0.12 | +25% | 0.37 | 0.36 | +3% |
| SBC MEDICAL GROUP HOLDINGS INCORPORATED UNAUDITED CONSOLIDATED BALANCE SHEETS | ||||||||
| September 30, 2026 | December 31, 2025 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 198,428,275 | $ | 163,773,838 | ||||
| Time deposits | 4,000,000 | — | ||||||
| Accounts receivable | 2,540,219 | 2,388,021 | ||||||
| Accounts receivable – related parties | 30,931,517 | 27,511,730 | ||||||
| Inventories | 2,949,218 | 2,792,617 | ||||||
| Short-term investments – related parties | 318,297 | 319,193 | ||||||
| Finance lease receivables, current – related parties | 16,143,695 | 12,832,355 | ||||||
| Income tax recoverable | 1,292,660 | 1,175,510 | ||||||
| Customer loans receivable, current | 3,966,531 | 8,705,999 | ||||||
| Prepaid expenses and other current assets | 10,762,659 | 11,724,852 | ||||||
| Prepaid expenses and other receivables – related parties | 2,522,970 | — | ||||||
| Total current assets | 273,856,041 | 231,224,115 | ||||||
| Non-current assets: | ||||||||
| Property and equipment, net | 8,527,530 | 7,539,392 | ||||||
| Intangible assets, net | 45,226,994 | 47,742,888 | ||||||
| Long-term investments, net | 1,880,112 | 1,299,366 | ||||||
| Equity method investments | 19,157,291 | 20,312,642 | ||||||
| Goodwill, net | 15,075,256 | 15,432,061 | ||||||
| Finance lease receivables, non-current – related parties | 14,448,126 | 13,746,513 | ||||||
| Operating lease right-of-use assets | 10,150,912 | 8,366,569 | ||||||
| Finance lease right-of-use assets | 277,827 | 450,874 | ||||||
| Deferred tax assets | 8,000,383 | 4,014,294 | ||||||
| Customer loans receivable, non-current | 2,325,289 | 4,824,977 | ||||||
| Long-term prepayments | 522,473 | 393,270 | ||||||
| Long-term investments in MCs – related parties | 17,787,217 | 17,837,293 | ||||||
| Other assets | 7,587,608 | 7,263,692 | ||||||
| Total non-current assets | 150,967,018 | 149,223,831 | ||||||
| Total assets | $ | 424,823,059 | $ | 380,447,946 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 23,408,185 | $ | 16,988,384 | ||||
| Accounts payable – related parties | 918,135 | 651,463 | ||||||
| Bank and other borrowings, current | 8,757,956 | 9,099,046 | ||||||
| Advances from customers | 877,664 | 1,415,762 | ||||||
| Advances from customers – related parties | 3,600,523 | 5,357,221 | ||||||
| Income tax payable | 16,707,822 | 8,821,853 | ||||||
| Operating lease liabilities, current | 5,754,161 | 4,416,960 | ||||||
| Finance lease liabilities, current | 88,091 | 132,946 | ||||||
| Accrued liabilities and other current liabilities | 14,552,613 | 11,544,695 | ||||||
| Due to related party | — | 2,692,673 | ||||||
| Total current liabilities | 74,665,150 | 61,121,003 | ||||||
| Non-current liabilities: | ||||||||
| Bank and other borrowings, non-current | 24,845,177 | 33,734,438 | ||||||
| Deferred tax liabilities | 15,614,455 | 16,374,832 | ||||||
| Operating lease liabilities, non-current | 4,541,685 | 4,136,257 | ||||||
| Finance lease liabilities, non-current | 62,857 | 116,527 | ||||||
| Other liabilities | 1,620,786 | 1,660,183 | ||||||
| Total non-current liabilities | 46,684,960 | 56,022,237 | ||||||
| Total liabilities | 121,350,110 | 117,143,240 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock ($0.0001 par value, 20,000,000 shares authorized; no shares issued and outstanding as of September 30, 2026 and December 31, 2025) | — | — | ||||||
| Common stock ($0.0001 par value, 400,000,000 shares authorized, 103,881,251 shares issued, and 102,576,943 shares outstanding as of September 30, 2026 and December 31, 2025) | 10,388 | 10,388 | ||||||
| Additional paid-in capital | 75,660,743 | 72,867,424 | ||||||
| Treasury stock (at cost, 1,304,308 shares as of September 30, 2026 and December 31, 2025) | (7,749,997 | ) | (7,749,997 | ) | ||||
| Retained earnings | 278,142,255 | 240,448,620 | ||||||
| Accumulated other comprehensive loss | (59,214,802 | ) | (57,294,239 | ) | ||||
| Total SBC Medical Group Holdings Incorporated stockholders’ equity | 286,848,587 | 248,282,196 | ||||||
| Non-controlling interests | 16,624,362 | 15,022,510 | ||||||
| Total stockholders’ equity | 303,472,949 | 263,304,706 | ||||||
| Total liabilities and stockholders’ equity | $ | 424,823,059 | $ | 380,447,946 | ||||
| SBC MEDICAL GROUP HOLDINGS INCORPORATED UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME | |||||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| Revenues, net – related parties | $ | 53,518,360 | $ | 39,617,548 | $ | 135,205,614 | $ | 123,819,591 | |||||||||
| Revenues, net | 5,063,160 | 3,735,687 | 15,624,536 | 10,221,192 | |||||||||||||
| Total revenues, net | 58,581,520 | 43,353,235 | 150,830,150 | 134,040,783 | |||||||||||||
| Cost of revenues (including cost of revenues from related parties of $1,749,587 and $4,018,377 for the three months ended September 30, 2026 and 2025, and $2,012,569 and $12,144,907 for the nine months ended September 30, 2026 and 2025, respectively) | 16,402,500 | 12,741,748 | 42,327,080 | 35,685,635 | |||||||||||||
| Gross profit | 42,179,020 | 30,611,487 | 108,503,070 | 98,355,148 | |||||||||||||
| Operating expenses: | |||||||||||||||||
| Selling, general and administrative expenses (including selling, general and administrative expenses from related parties of $877,328 and $154,063 for the three months ended September 30, 2026 and 2025, and $1,562,231 and $569,830 for the nine months ended September 30, 2026 and 2025, respectively) | 15,761,753 | 14,730,247 | 45,405,238 | 43,717,642 | |||||||||||||
| Total operating expenses | 15,761,753 | 14,730,247 | 45,405,238 | 43,717,642 | |||||||||||||
| Income from operations | 26,417,267 | 15,881,240 | 63,097,832 | 54,637,506 | |||||||||||||
| Other income (expenses): | |||||||||||||||||
| Interest income (including interest income from related parties of $1,582 and nil for the three months ended September 30, 2026 and 2025, and $5,047 and nil for the nine months ended September 30, 2026 and 2025, respectively) | 344,937 | 120,384 | 474,826 | 198,599 | |||||||||||||
| Interest expense | (128,878 | ) | (48,635 | ) | (372,313 | ) | (104,493 | ) | |||||||||
| Foreign currency exchange gain (loss), net | (947,087 | ) | 923,671 | 946,850 | (904,575 | ) | |||||||||||
| Other income (including other income from related parties of nil and $3,069 for the three months ended September 30, 2026 and 2025, and nil and $3,069 for the nine months ended September 30, 2026 and 2025, respectively) | 695,294 | 1,632,527 | 1,323,914 | 1,929,258 | |||||||||||||
| Other expenses | — | (2,323 | ) | (678,279 | ) | (1,003,801 | ) | ||||||||||
| Gain on redemption of life insurance policies | — | — | — | 8,746,138 | |||||||||||||
| Total other income (expenses) | (35,734 | ) | 2,625,624 | 1,694,998 | 8,861,126 | ||||||||||||
| Income before income taxes and equity in losses of equity method investees | 26,381,533 | 18,506,864 | 64,792,830 | 63,498,632 | |||||||||||||
| Income tax expense | (9,378,075 | ) | (5,673,538 | ) | (24,729,409 | ) | (26,733,504 | ) | |||||||||
| Equity in losses of equity method investees, net of tax | (586,699 | ) | — | (1,155,351 | ) | — | |||||||||||
| Net income | 16,416,759 | 12,833,326 | 38,908,070 | 36,765,128 | |||||||||||||
| Less: net income (loss) attributable to non-controlling interests | 724,017 | 8,690 | 1,214,435 | (20,194 | ) | ||||||||||||
| Net income attributable to SBC Medical Group Holdings Incorporated | $ | 15,692,742 | $ | 12,824,636 | $ | 37,693,635 | $ | 36,785,322 | |||||||||
| Other comprehensive income (loss): | |||||||||||||||||
| Foreign currency translation adjustment | $ | 7,066,384 | $ | (6,791,961 | ) | $ | (2,502,636 | ) | $ | 11,639,635 | |||||||
| Total comprehensive income | 23,483,143 | 6,041,365 | 36,405,434 | 48,404,763 | |||||||||||||
| Less: comprehensive income attributable to non-controlling interests | 415,698 | 10,329 | 632,362 | 157,908 | |||||||||||||
| Comprehensive income attributable to SBC Medical Group Holdings Incorporated | $ | 23,067,445 | $ | 6,031,036 | $ | 35,773,072 | $ | 48,246,855 | |||||||||
| Net income per share attributable to SBC Medical Group Holdings Incorporated | |||||||||||||||||
| Basic and diluted | $ | 0.15 | $ | 0.12 | $ | 0.37 | $ | 0.36 | |||||||||
| Weighted average shares outstanding | |||||||||||||||||
| Basic and diluted | 102,576,943 | 102,642,634 | 102,576,943 | 103,139,851 | |||||||||||||
| SBC MEDICAL GROUP HOLDINGS INCORPORATED UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
| For the Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net income | $ | 38,908,070 | $ | 36,765,128 | ||||
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||||||||
| Depreciation and amortization expense | 2,979,917 | 2,010,616 | ||||||
| Non-cash lease expense | 4,239,772 | 3,436,789 | ||||||
| Provision for (reversal of) credit losses | (22,236 | ) | 305,963 | |||||
| Equity in losses of equity method investees | 1,155,351 | — | ||||||
| Stock-based compensation | 19,541 | — | ||||||
| Fair value change of long-term investments | (579,154 | ) | (724,476 | ) | ||||
| Gain on redemption of life insurance policies | — | (8,746,138 | ) | |||||
| Loss (gain) on disposal of property and equipment | 9,375 | (414,167 | ) | |||||
| Change in fair value of cryptocurrencies | — | (146,036 | ) | |||||
| Deferred income taxes | (4,386,410 | ) | 9,104,235 | |||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (197,484 | ) | (1,084,316 | ) | ||||
| Accounts receivable – related parties | (3,502,443 | ) | (28,031,690 | ) | ||||
| Inventories | (191,314 | ) | 265,052 | |||||
| Finance lease receivables – related parties | (4,050,925 | ) | (9,227,612 | ) | ||||
| Customer loans receivable | 7,158,848 | 12,153,263 | ||||||
| Prepaid expenses and other current assets | 923,442 | (2,180,695 | ) | |||||
| Prepaid expenses and other receivables – related parties | (2,500,352 | ) | — | |||||
| Long-term prepayments | (375,662 | ) | 281,666 | |||||
| Other assets | (390,302 | ) | 77,609 | |||||
| Accounts payable | 6,551,564 | 2,549,938 | ||||||
| Accounts payable – related parties | 280,593 | 2,144,314 | ||||||
| Notes payable – related parties | — | (12,759,536 | ) | |||||
| Advances from customers | (528,982 | ) | 161,165 | |||||
| Advances from customers – related parties | (1,726,044 | ) | (5,470,844 | ) | ||||
| Income tax payable | 7,711,189 | (19,936,155 | ) | |||||
| Operating lease liabilities | (4,279,802 | ) | (3,639,887 | ) | ||||
| Accrued liabilities and other current liabilities | 3,059,724 | (4,096,471 | ) | |||||
| Other liabilities | (18,888 | ) | (93,141 | ) | ||||
| NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES | 50,247,388 | (27,295,426 | ) | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Purchase of property and equipment | (1,214,421 | ) | (603,484 | ) | ||||
| Prepayments for property and equipment | (888,098 | ) | (838,568 | ) | ||||
| Payments made on behalf of related parties | — | (1,840,801 | ) | |||||
| Purchase of long-term investments | — | (654,070 | ) | |||||
| Placement of time deposits | (4,000,000 | ) | — | |||||
| Purchase of cryptocurrencies | — | (424,250 | ) | |||||
| Cash paid for acquisition of subsidiaries, net of cash acquired | — | (14,861,858 | ) | |||||
| Long-term loans to others | — | (14,514 | ) | |||||
| Repayments from related parties | — | 1,911,440 | ||||||
| Repayments from others | 41,765 | 73,928 | ||||||
| Proceeds from redemption of life insurance policies | — | 17,735,717 | ||||||
| Deconsolidation of VIE, net of cash disposed of | 1,019,909 | — | ||||||
| Proceeds from disposal of property and equipment | — | 2,755,983 | ||||||
| NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES | (5,040,845 | ) | 3,239,523 | |||||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Borrowings from bank and others | — | 14,851,980 | ||||||
| Borrowings from related parties | — | 15,000 | ||||||
| Proceeds from exercise of stock acquisition rights in subsidiary by non-controlling interests | 94,843 | — | ||||||
| Repayments of bank and other borrowings | (8,912,553 | ) | (721,874 | ) | ||||
| Repayments of finance lease liabilities | (99,932 | ) | (310,603 | ) | ||||
| Repayments to related parties | (22,657 | ) | (46,782 | ) | ||||
| Repurchase of common stock | — | (4,999,997 | ) | |||||
| Deemed contribution in connection with price modification on disposal of property and equipment | — | 9,682,277 | ||||||
| NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES | (8,940,299 | ) | 18,470,001 | |||||
| Effect of exchange rate changes | (1,611,807 | ) | 7,973,128 | |||||
| NET CHANGE IN CASH AND CASH EQUIVALENTS | 34,654,437 | 2,387,226 | ||||||
| CASH AND CASH EQUIVALENTS AS OF THE BEGINNING OF THE PERIOD | 163,773,838 | 125,044,092 | ||||||
| CASH AND CASH EQUIVALENTS AS OF THE END OF THE PERIOD | $ | 198,428,275 | $ | 127,431,318 | ||||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||||||||
| Cash paid for interest expense | $ | 372,313 | $ | 104,493 | ||||
| Cash paid for income taxes, net | $ | 21,135,092 | $ | 37,555,740 | ||||
| NON-CASH INVESTING AND FINANCING ACTIVITIES | ||||||||
| Property and equipment transferred from prepaid expenses | $ | 57,013 | $ | — | ||||
| Property and equipment transferred from long-term prepayments | $ | 1,050,946 | $ | 1,428,254 | ||||
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | $ | 221,443 | $ | 105,556 | ||||
| Finance lease right-of-use assets obtained in exchange for finance lease liabilities | $ | — | $ | 612,466 | ||||
| Remeasurement of operating lease liabilities and right-of-use assets due to lease modifications | $ | 5,845,817 | $ | 2,646,028 | ||||
| Payables to related parties in connection with loan services provided | $ | — | $ | 14,362,902 | ||||
| Issuance of common stock as incentive shares | $ | — | $ | 86 | ||||
| RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (UNAUDITED) SBC MEDICAL GROUP HOLDINGS INCORPORATED | ||||||||||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Total revenues, net | $ | 58,581,520 | $ | 43,353,235 | $ | 150,830,150 | $ | 134,040,783 | ||||||||||||||
| Net income attributable to SBC Medical Group Holdings Incorporated | 15,692,742 | 12,824,636 | 37,693,635 | 36,785,322 | ||||||||||||||||||
| Adjusted to add (deduct) the following: | ||||||||||||||||||||||
| Net income (loss) attributable to non-controlling interests | 724,017 | 8,690 | 1,214,435 | (20,194 | ) | |||||||||||||||||
| Equity in losses of equity method investees, net of tax | 586,699 | — | 1,155,351 | — | ||||||||||||||||||
| Income tax expense | 9,378,075 | 5,673,538 | 24,729,409 | 26,733,504 | ||||||||||||||||||
| Gain on redemption of life insurance policies | — | — | — | (8,746,138 | ) | |||||||||||||||||
| Other expenses | — | 2,323 | 678,279 | 1,003,801 | ||||||||||||||||||
| Other income | (695,294 | ) | (1,632,527 | ) | (1,323,914 | ) | (1,929,258 | ) | ||||||||||||||
| Foreign currency exchange loss (gain), net | 947,087 | (923,671 | ) | (946,850 | ) | 904,575 | ||||||||||||||||
| Interest expense | 128,878 | 48,635 | 372,313 | 104,493 | ||||||||||||||||||
| Interest income | (344,937 | ) | (120,384 | ) | (474,826 | ) | (198,599 | ) | ||||||||||||||
| Depreciation and amortization expense | 1,176,959 | 746,211 | 2,979,917 | 2,010,616 | ||||||||||||||||||
| Adjusted EBITDA | $ | 27,594,226 | $ | 16,627,451 | $ | 66,077,749 | $ | 56,648,122 | ||||||||||||||
| Net income margin | 27 | % | 30 | % | 25 | % | 27 | % | ||||||||||||||
| Adjusted EBITDA margin | 47 | % | 38 | % | 44 | % | 42 | % | ||||||||||||||